Abstract-Type 2 bradykinin (B 2 )-receptor antagonists have been used to define the role of endogenous kinin peptides. However, interpretation of the effects of B 2 -receptor antagonists has been limited by lack of information concerning the effects of these antagonists on endogenous kinin and angiotensin peptide levels. If kinin levels were subject to short-loop-feedback regulation mediated through B 2 receptors, then a reactive increase in kinin levels might blunt the effects of B 2 -receptor antagonism and stimulate type 1 bradykinin receptors. Moreover, kinins have been implicated in the control of renin secretion. We investigated whether endogenous kinin levels are subject to short-loop-feedback regulation mediated by the B 2 receptor and whether endogenous kinins acting through the B 2 receptor influence plasma renin levels and circulating and tissue angiotensin peptide levels. The B 2 -receptor antagonist icatibant (1 mg/kg) was administered to rats by intraperitoneal injection, and circulating and tissue levels of angiotensin and kinin peptides were measured after 4 hours. Icatibant produced 75% occupancy of B 2 receptors in the inner stripe of the renal medulla. Icatibant did not influence plasma levels of renin, angiotensinogen, angiotensin-converting enzyme, neutral endopeptidase, or circulating or tissue levels of angiotensin and bradykinin peptides. This study demonstrated that kinin levels are not subject to short-loopfeedback regulation mediated through B 2 receptors and that endogenous kinin levels acting through the B 2 receptor do not modulate the renin-angiotensin system. (Hypertension. 1999;33:1233-1236.)
T he nonapeptide bradykinin [BK (1) (2) (3) (4) (5) (6) (7) (8) (9) ] has important actions on blood vessels, heart, and kidney. There are 2 types of kinin receptor, the type 1 (B 1 ) and the type 2 (B 2 ) receptors. By far the most important hemodynamic effect of BK (1) (2) (3) (4) (5) (6) (7) (8) (9) in vivo is the hypotensive vasodilatation produced by stimulation of endothelial B 2 receptors of arteries and arterioles, with subsequent endothelial release of nitric oxide and prostaglandins. 1 Additional renal actions of BK (1) (2) (3) (4) (5) (6) (7) (8) (9) include the production of diuresis and natriuresis. 2, 3 Whereas the diuretic effect of BK (1) (2) (3) (4) (5) (6) (7) (8) (9) administered by the renal artery is mediated by B 2 receptors, both B 1 and B 2 receptors may participate in BK(1-9)-induced natriuresis and increase in renal blood flow. [3] [4] [5] B 1 receptors are induced by tissue injury, such as that which occurs after myocardial ischemia 6 and inflammation. 7 The role of endogenous kinins has been determined mainly by study of the effects of kinin antagonists, most often the B 2 -receptor antagonist icatibant (D-Arg-[Hyp 3 ,Thi 5 ,D-Tic 7 ,Oic 8 ]-bradykinin). 5,8 -11 However, interpretation of the effects of B 2 -receptor antagonists has been limited by lack of information concerning the effects of these antagonists on endogenous kinin levels. If kinin levels were subject to short-loop-feedback regulation mediated by B 2 receptors, then a reactive increase in kinin levels may blunt the effects of B 2 -receptor antagonism and stimulate B 1 receptors. In support of a feedback regulation of kinin levels mediated by the B 2 receptor, icatibant administration for 7 days is reported to increase kallikrein activity, but not kallikrein mRNA levels, in kidney of adult rats. 11 Moreover, Siragy et al 5 report that icatibant increases renal interstitial BK(1-9) levels in dogs in low-sodium balance.
One consequence of B 2 -receptor antagonism may be a change in angiotensin II (Ang II) levels. Kinin administration increases renin secretion, 12, 13 possibly mediated by increased nitric oxide formation, 14 and icatibant is reported to decrease plasma renin levels in anesthetized rabbits, 8 which suggests that endogenous kinins may tonically stimulate renin secretion. Moreover, the location of B 2 receptors in the kidney is predominantly in the renal tubules, vascular endothelium, and renomedullary interstitial cells of the renal medulla, 15 locations appropriate for the modification of renin secretion, possibly by the modification of sodium delivery to the macula densa.
The purpose of this study was to determine whether endogenous kinin levels are subject to short-loop-feedback regulation through the B 2 receptor, and whether endogenous kinins acting through the B 2 receptor influence plasma renin levels and circulating and tissue angiotensin peptide levels.
Methods

Animals
Male Sprague-Dawley rats (Ϸ300 g) were allowed free access to tap water and standard rat chow that contained 0.25% sodium and 0.76% potassium (GR2, Clarke-King & Co). This study was performed in accordance with the guidelines of the Animal Experimentation Ethics Committee of St Vincent's Hospital.
Rats (nϭ9 to 10 per group) were given 0.3 mg icatibant (1 mg/kg) in 0.5 mL 0.15 mol/L sodium chloride, or 0.5 mL vehicle, by intraperitoneal injection. After 4 hours, the rats were killed by decapitation, and trunk blood was collected for the measurement of plasma levels of angiotensin-converting enzyme (ACE), neutral endopeptidase 24.11 (NEP), renin, angiotensinogen, and angiotensin peptides. The left kidney, heart (cardiac ventricles), lung, and aorta were rapidly removed, weighed, and immediately homogenized in 4 mol/L guanidine thiocyanate, 1% trifluoroacetic acid (GTC/TFA) for the measurement of tissue levels of angiotensin and bradykinin peptides. The right kidney was frozen in isopentane cooled to the temperature of dry ice for in vitro autoradiography. Blood bradykinin peptides were measured in separate groups of rats (nϭ9 to 10 per group) given icatibant or vehicle by identical protocols. After 4 hours, these rats were anesthetized with diethyl ether, and 2 mL blood was collected from the inferior vena cava in syringes that contained 10 mL GTC/TFA for the measurement of bradykinin peptides. Icatibant was a generous gift from Hoechst AG, Frankfurt, Germany.
Extraction and Radioimmunoassay of Angiotensin and Bradykinin Peptides
Plasma levels of Ang II and angiotensin I (Ang I) were measured as described previously. 16 Briefly, trunk blood (2 to 3 mL) was rapidly collected in tubes that contained 0.5 mL inhibitor solution (1 mmol/L renin inhibitor acetyl-His-Pro-Phe-Val-Sta-Leu-Phe-NH 2 , 17 146 mol/L pepstatin, 50 mmol/L 1,10-phenanthroline, 125 mmol/L EDTA, 2 g/l neomycin sulfate, 2% dimethyl sulfoxide, and 2% ethanol in water) at 4°C. The blood was centrifuged, and the plasma (1 to 2 mL) was immediately extracted with Sep-Pak C 18 cartridges (Waters Chromatography Division). Blood and tissues homogenized in GTC/TFA were processed as described previously and extracted with Sep-Pak C 18 cartridges. 16 Peptides were acetylated and treated with piperidine before high-performance liquid chromatography (HPLC) and assay of HPLC fractions by N-terminal directed radioimmunoassay. 16 Data were corrected for recovery as reported elsewhere. 16, 18 
Measurement of ACE, NEP, Renin, and Angiotensinogen in Plasma
Trunk blood used for measurement of ACE, NEP, renin, and angiotensinogen was collected in heparinized tubes on ice, then centrifuged. The plasma was rapidly frozen on dry ice and stored at Ϫ80°C. ACE activity was measured with the use of 3-(2-furylacryloyl)-L-phenylalanyl-glycyl-glycine as substrate. 19 NEP enzymatic activity was measured with succinyl-Ala-Ala-Pheamidomethylcoumarin as substrate 20 ; further incubation with aminopeptidase M released free amidomethylcoumarin that was measured fluorometrically. The plasma concentrations of active renin and angiotensinogen were measured as described previously. 21 
In Vitro Autoradiography
Cryostat sections of kidney (20 m) were cut and mounted on gelatin-chrome alum-coated slides. In vitro autoradiography was performed as described by Dean et al, 15 
Statistical Analysis
Data are presented as meanϮSEM. Comparisons with vehicletreated rats were made with a 2-tailed t test. If more than half the samples of a mean had values less than the minimum detectable for that particular assay, then the sample mean is shown as less than the minimum detectable. If values were below the minimum detectable, then they were set at half the minimum detectable for statistical calculations. Logarithmic transformation of the data was performed when necessary to obtain similar variances between groups. All tests were 2-tailed. Differences were considered significant at PϽ0.05. Statistical analyses were performed with SuperANOVA (Abacus Concepts, Inc). Detectable differences were calculated with SamplePower (SPPS).
Results
In vitro autoradiography of cryostat sections of kidney showed that in vivo administration of icatibant produced 75% inhibition of binding of 125 I-HPP-icatibant to the inner stripe of the renal medulla, the main site of B 2 receptors in kidney. However, icatibant administration did not modify circulating or tissue levels of kinin or angiotensin peptides or plasma levels of ACE, NEP, renin, or angiotensinogen (Tables 1 to 3) .
When the data were analyzed for each peptide in each tissue, this study had 80% power (␣ϭ0.05, tailsϭ2) to detect a difference in kinin or angiotensin peptide levels of 40% to 100% of control values. This is an underestimation of power and overestimation of detectable differences because multiple comparisons were performed. Moreover, this study had an 80% power to detect a 74% change in renin levels.
Discussion
This study demonstrated that endogenous kinin levels were not subject to short-loop-feedback regulation mediated by the B 2 receptor and that endogenous kinins acting through the B 2 receptor did not influence plasma renin levels or circulating or tissue angiotensin peptide levels. These data are essential for the interpretation of the effects of B 2 -receptor antagonism because the data exclude the possibility of a reactive rise in endogenous kinin levels that may blunt the effects of B 2 -receptor antagonism and stimulate B 1 receptors and because the data exclude an effect of icatibant on Ang II levels. Our results are consistent with the lack of effect of icatibant on mRNA levels for kallikrein, B 2 receptor, and ACE in kidney. 11 However, our results are not consistent with the reported increase in renal kallikrein activity in response to icatibant, 11 and differ from the report by Siragy et al 5 of increased renal interstitial BK(1-9) levels in response to icatibant. The difference between our results and those of Siragy et al 5 may be due to differences between species or to the low-sodium diet of the dogs studied by Siragy et al. 5 We used in vitro autoradiography of 125 I-HPP-icatibant binding to kidney sections to demonstrate effective blockade of B 2 receptors by icatibant. Other studies have shown that similar or lower doses of icatibant block the depressor effects of BK(1-9) in rats. 4, 9 Little is known about the regulation of endogenous kinin levels, although there are interrelationships between the kinin and angiotensin systems. Whereas ACE inhibition increases endogenous kinin levels, presumably by inhibition of kinin metabolism, 22 there is little information concerning the factors that may modulate kinin production. Both the kinin and angiotensin systems are involved in fluid and electrolyte homeostasis. Sodium depletion stimulates renin secretion and also increases kinin levels in microdialysate fluid from dog kidney, 23 an effect inhibited by concomitant renin inhibition. 24 Furthermore, Ang II stimulation of nitric oxide and cyclic GMP production in vasculature is dependent on the action of kinins on the B 2 receptor. 25, 26 Moreover, AT 1 -receptor antagonism reduces kinin levels in blood and kidney of Sprague-Dawley rats, 27 whereas kinin levels are increased in lung and brown adipose tissue of the TGR(mRen-2)27 rat, a high-angiotensin model of hypertension. 28 These studies suggest that Ang II may be a tonic positive regulator of kinin levels. Despite evidence that suggests a role for kinins in the regulation of renin secretion, 8, 12, 13 the results of the present study do not support a reciprocal relationship whereby endogenous kinins regulate angiotensin peptide levels. The present results are limited to the effect of B 2 -receptor antagonism of 4-hour duration. Longer periods of B 2 -receptor antagonism may have effects on kinin and angiotensin peptide levels, which may be mediated by longer-term changes in fluid and electrolyte homeostasis. However, evidence against this possibility includes the failure of icatibant administration for 7 days to modify renin mRNA levels in kidney of adult rats 11 and the normal plasma renin levels and normal renin and AT 1 receptor mRNA levels in kidney of the B 2 -receptor gene knockout mouse. 29 
